tetano
Editor, Senior Moderator
Science
. 2020 Nov 6;eabe1107.
doi: 10.1126/science.abe1107. Online ahead of print.
Preexisting and de novo humoral immunity to SARS-CoV-2 in humans
Kevin W Ng[SUP] #[/SUP][SUP] 1 [/SUP], Nikhil Faulkner[SUP] #[/SUP][SUP] 1 [/SUP], Georgina H Cornish[SUP] #[/SUP][SUP] 1 [/SUP], Annachiara Rosa[SUP] #[/SUP][SUP] 2 [/SUP], Ruth Harvey[SUP] 3 [/SUP], Saira Hussain[SUP] 3 [/SUP], Rachel Ulferts[SUP] 4 [/SUP], Christopher Earl[SUP] 5 [/SUP], Antoni G Wrobel[SUP] 6 [/SUP], Donald J Benton[SUP] 6 [/SUP], Chloe Roustan[SUP] 7 [/SUP], William Bolland[SUP] 1 [/SUP], Rachael Thompson[SUP] 1 [/SUP], Ana Agua-Doce[SUP] 8 [/SUP], Philip Hobson[SUP] 8 [/SUP], Judith Heaney[SUP] 9 [/SUP], Hannah Rickman[SUP] 9 [/SUP], Stavroula Paraskevopoulou[SUP] 9 [/SUP], Catherine F Houlihan[SUP] 9 10 [/SUP], Kirsty Thomson[SUP] 9 [/SUP], Emilie Sanchez[SUP] 9 [/SUP], Gee Yen Shin[SUP] 9 [/SUP], Moira J Spyer[SUP] 9 11 [/SUP], Dhira Joshi[SUP] 12 [/SUP], Nicola O'Reilly[SUP] 12 [/SUP], Philip A Walker[SUP] 7 [/SUP], Svend Kjaer[SUP] 7 [/SUP], Andrew Riddell[SUP] 8 [/SUP], Catherine Moore[SUP] 13 [/SUP], Bethany R Jebson[SUP] 14 15 [/SUP], Meredyth Wilkinson[SUP] 14 15 [/SUP], Lucy R Marshall[SUP] 14 15 [/SUP], Elizabeth C Rosser[SUP] 14 16 [/SUP], Anna Radziszewska[SUP] 14 16 [/SUP], Hannah Peckham[SUP] 14 16 [/SUP], Coziana Ciurtin[SUP] 14 16 [/SUP], Lucy R Wedderburn[SUP] 14 15 [/SUP], Rupert Beale[SUP] 4 [/SUP], Charles Swanton[SUP] 17 [/SUP], Sonia Gandhi[SUP] 18 [/SUP], Brigitta Stockinger[SUP] 19 [/SUP], John McCauley[SUP] 3 [/SUP], Steve J Gamblin[SUP] 6 [/SUP], Laura E McCoy[SUP] 20 [/SUP], Peter Cherepanov[SUP] 21 [/SUP], Eleni Nastouli[SUP] 22 11 [/SUP], George Kassiotis[SUP] 23 24 [/SUP]
Affiliations
Abstract
Zoonotic introduction of novel coronaviruses may encounter preexisting immunity in humans. Using diverse assays for antibodies recognizing SARS-CoV-2 proteins, we detect preexisting humoral immunity. SARS-CoV-2 spike glycoprotein (S)-reactive antibodies were detectable by a flow cytometry-based method in SARS-CoV-2-uninfected individuals and were particularly prevalent in children and adolescents. They were predominantly of the IgG class and targeted the S2 subunit. By contrast, SARS-CoV-2 infection induced higher titers of SARS-CoV-2 S-reactive IgG antibodies, targeting both the S1 and S2 subunits, and concomitant IgM and IgA antibodies, lasting throughout the observation period. Notably, SARS-CoV-2-uninfected donor sera exhibited specific neutralizing activity against SARS-CoV-2 and SARS-CoV-2 S pseudotypes. Distinguishing preexisting and de novo immunity will be critical for our understanding of susceptibility to and the natural course of SARS-CoV-2 infection.
. 2020 Nov 6;eabe1107.
doi: 10.1126/science.abe1107. Online ahead of print.
Preexisting and de novo humoral immunity to SARS-CoV-2 in humans
Kevin W Ng[SUP] #[/SUP][SUP] 1 [/SUP], Nikhil Faulkner[SUP] #[/SUP][SUP] 1 [/SUP], Georgina H Cornish[SUP] #[/SUP][SUP] 1 [/SUP], Annachiara Rosa[SUP] #[/SUP][SUP] 2 [/SUP], Ruth Harvey[SUP] 3 [/SUP], Saira Hussain[SUP] 3 [/SUP], Rachel Ulferts[SUP] 4 [/SUP], Christopher Earl[SUP] 5 [/SUP], Antoni G Wrobel[SUP] 6 [/SUP], Donald J Benton[SUP] 6 [/SUP], Chloe Roustan[SUP] 7 [/SUP], William Bolland[SUP] 1 [/SUP], Rachael Thompson[SUP] 1 [/SUP], Ana Agua-Doce[SUP] 8 [/SUP], Philip Hobson[SUP] 8 [/SUP], Judith Heaney[SUP] 9 [/SUP], Hannah Rickman[SUP] 9 [/SUP], Stavroula Paraskevopoulou[SUP] 9 [/SUP], Catherine F Houlihan[SUP] 9 10 [/SUP], Kirsty Thomson[SUP] 9 [/SUP], Emilie Sanchez[SUP] 9 [/SUP], Gee Yen Shin[SUP] 9 [/SUP], Moira J Spyer[SUP] 9 11 [/SUP], Dhira Joshi[SUP] 12 [/SUP], Nicola O'Reilly[SUP] 12 [/SUP], Philip A Walker[SUP] 7 [/SUP], Svend Kjaer[SUP] 7 [/SUP], Andrew Riddell[SUP] 8 [/SUP], Catherine Moore[SUP] 13 [/SUP], Bethany R Jebson[SUP] 14 15 [/SUP], Meredyth Wilkinson[SUP] 14 15 [/SUP], Lucy R Marshall[SUP] 14 15 [/SUP], Elizabeth C Rosser[SUP] 14 16 [/SUP], Anna Radziszewska[SUP] 14 16 [/SUP], Hannah Peckham[SUP] 14 16 [/SUP], Coziana Ciurtin[SUP] 14 16 [/SUP], Lucy R Wedderburn[SUP] 14 15 [/SUP], Rupert Beale[SUP] 4 [/SUP], Charles Swanton[SUP] 17 [/SUP], Sonia Gandhi[SUP] 18 [/SUP], Brigitta Stockinger[SUP] 19 [/SUP], John McCauley[SUP] 3 [/SUP], Steve J Gamblin[SUP] 6 [/SUP], Laura E McCoy[SUP] 20 [/SUP], Peter Cherepanov[SUP] 21 [/SUP], Eleni Nastouli[SUP] 22 11 [/SUP], George Kassiotis[SUP] 23 24 [/SUP]
Affiliations
- PMID: 33159009
- DOI: 10.1126/science.abe1107
Abstract
Zoonotic introduction of novel coronaviruses may encounter preexisting immunity in humans. Using diverse assays for antibodies recognizing SARS-CoV-2 proteins, we detect preexisting humoral immunity. SARS-CoV-2 spike glycoprotein (S)-reactive antibodies were detectable by a flow cytometry-based method in SARS-CoV-2-uninfected individuals and were particularly prevalent in children and adolescents. They were predominantly of the IgG class and targeted the S2 subunit. By contrast, SARS-CoV-2 infection induced higher titers of SARS-CoV-2 S-reactive IgG antibodies, targeting both the S1 and S2 subunits, and concomitant IgM and IgA antibodies, lasting throughout the observation period. Notably, SARS-CoV-2-uninfected donor sera exhibited specific neutralizing activity against SARS-CoV-2 and SARS-CoV-2 S pseudotypes. Distinguishing preexisting and de novo immunity will be critical for our understanding of susceptibility to and the natural course of SARS-CoV-2 infection.